Length of Diagnostic Delay in Patients with Non-small-cell Lung Cancer

被引:0
作者
Valdes, Solangel [1 ]
Garcia, Eberto [1 ]
Perez, Hayvin [1 ]
Hernandez, Marisela [1 ]
机构
[1] Hosp Neumol Benef Jurid, Havana, Cuba
关键词
Lung cancer; non-small-cell lung carcinoma; diagnosis; delivery of health care; SYMPTOMS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Despite advances in diagnostic techniques and treatment, lung cancer is the leading cause of cancer death worldwide and in Cuba. Prompt initiation of cancer therapy depends on rapid diagnostic confirmation; however, most patients are diagnosed at an advanced stage. In the Cuban health system, primary, secondary and tertiary levels of care are interrelated; patients may seek care at any level or may be referred from one to another. Lung cancer diagnoses are confirmed at the tertiary level. Objective Determine the length of diagnostic delay in patients diagnosed with non-small-cell lung cancer (NSCLC) at a tertiary care facility in Havana, Cuba, as well as mean diagnostic delay attributable to the patient and to the health system by level of care. Methods A descriptive observational study of 96 patients with a cytologically and/or histologically confirmed diagnosis of non-small-cell lung cancer was conducted in 2005-2007. Patients initially sought care for disease symptoms at primary, secondary or tertiary levels in the Cuban public health system, but diagnosis of all patients was confirmed at a specialized tertiary care facility. Total diagnostic delay was calculated as the time elapsed from onset of symptoms to confirmation of NSCLC diagnosis. Variables also included diagnostic delay attributable to the patient and diagnostic delay attributable to the health system by level of care. Data were arranged in tables and analyzed by absolute value, percentage, mean, and standard deviation. Results Of the 96 patients studied, 69% were male, and 54% were aged 50-69 years. Fifty-five percent of patients sought medical care within 15 days of onset of symptoms, 21% within 16-30 days, and 3% waited >90 days. Mean diagnostic delay attributable to the patient was 18.19 +/- 3.45 days while mean diagnostic delay attributable to the health system was 61.63 +/- 18.50 days, and overall diagnostic delay was 73.13 +/- 17.53 days. For the 71% of patients seen in primary care, mean diagnostic delay was 29.51 +/- 4.53 days; for the 45% seen exclusively or additionally at the secondary level, mean diagnostic delay was 24.45 +/- 7.31 days. Upon admission at the tertiary care level, mean diagnostic confirmation delay was 18.23 +/- 3.68 days. Conclusions Diagnostic delay of lung cancer patients in this study was prolonged. Appropriate strategies are needed for reducing this delay.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [21] The diagnostic and prognostic role of circulating miR-141 expression in non-small-cell lung cancer patients
    Zhao, Yizhuo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (05): : 2597 - 2604
  • [22] Sleep quality in lung cancer and specifically non-small-cell lung cancer: a rapid review
    Prieur-Drevon, Daphne
    Pabst, Lucile
    Mascaux, Celine
    Sauleau, Erik-Andre
    Chevalier, Catherine
    Ruppert, Elisabeth
    Calvel, Laurent
    SUPPORTIVE CARE IN CANCER, 2025, 33 (02)
  • [23] Surgical management of non-small-cell lung cancer
    Bamousa, Ahmed
    AlKattan, Khaled
    ANNALS OF THORACIC MEDICINE, 2008, 3 (06) : S82 - S88
  • [24] Systemic therapy in non-small-cell lung cancer
    Jazieh, Abdul-Rahman
    Saadeen, Ahmed
    ANNALS OF THORACIC MEDICINE, 2008, 3 (06) : S97 - S99
  • [25] Surgical treatment of non-small-cell lung cancer
    Schuhan, C.
    Dienemann, H.
    ONKOLOGE, 2011, 17 (08): : 684 - +
  • [26] Developing a Vaccine for Non-Small-Cell Lung Cancer
    Santos, Edgardo S.
    Raez, Luis E.
    POSTGRADUATE MEDICINE, 2009, 121 (05) : 187 - 189
  • [27] Exploration of oxidized phosphocholine profile in non-small-cell lung cancer
    Godzien, Joanna
    Lopez-Lopez, Angeles
    Sieminska, Julia
    Jablonowski, Kacper
    Pietrowska, Karolina
    Kisluk, Joanna
    Mojsak, Malgorzata
    Dzieciol-Anikiej, Zofia
    Barbas, Coral
    Reszec, Joanna
    Kozlowski, Miroslaw
    Moniuszko, Marcin
    Kretowski, Adam
    Niklinski, Jacek
    Ciborowski, Michal
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 10
  • [28] The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States
    Cushman, Taylor R.
    Jones, Bernard
    Akhavan, David
    Rusthoven, Chad G.
    Verma, Vivek
    Salgia, Ravi
    Sedrak, Mina
    Massarelli, Erminia
    Welsh, James W.
    Amini, Arya
    CLINICAL LUNG CANCER, 2021, 22 (01) : E84 - E97
  • [29] Anthropometric measurements in non-small-cell lung cancer
    Giovanni Mantovani
    Supportive Care in Cancer, 2002, 10 : 439 - 439
  • [30] Mediastinal staging of non-small-cell lung cancer
    Dhillon, Samjot Singh
    Dhillon, Jaspreet Kaur
    Yendamuri, Sai
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (06) : 835 - 851